claim: oncogen researchers propose personalized vaccinomics strategy for the novel china coronavirus
evidence_1: the candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.", "technical details of the approach used are detailed below: we identified multiepitope peptide vaccine candidates against ncov that can potentially trigger both cd4+ and cd8+ t cell immune response.", "the approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "based on the human mhc (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.", "the selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (mhc) class i and ii molecules, and the relevant hla alleles.")